ClinicalTrials.gg
CompletedNCT05591755Updated Jul 1, 2025Results posted

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

A Phase 3 interventional study of Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution and Ketotifen fumarate ophthalmic solution 0.035% in Seasonal Allergic Conjunctivitis, sponsored by Bausch & Lomb Incorporated. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
229
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Conjunctivitis, Allergic by Bausch Health Companies Inc. — none open to participants now, none under way, none of them phase 3. Conjunctivitis, Allergic · Bausch Health Companies Inc..

Enrollment
7th of 17
229 · median 144
Started
2022
with 1 other
Phase 3
11 of 17
none open now
Registered
15th of 17
by date

Among the 17 studies in Conjunctivitis, Allergic by Bausch Health Companies Inc., this one is the 7th largest by enrollment, is one of 2 that started in 2022, is one of 11 in phase 3, and was the 15th registered.

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.

Browse Conjunctivitis, Allergic studies →

Open to participants now

None of the 17 studies in Conjunctivitis, Allergic by Bausch Health Companies Inc. is open now. The open studies under Conjunctivitis, Allergic, anywhere →

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Conjunctivitis, Allergic by Bausch Health Companies Inc. as a file.
02

Study summary

To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.

03

Conditions studied

  • Seasonal Allergic Conjunctivitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must:

    1. be at least 18 years of age of either sex and any race;
    2. provide written and sign the Health Information Portability and Accountability Act (HIPAA) form;
    3. be willing and able to follow all instructions and attend all study visits;
    4. provide proof of COVID-19 vaccination
    5. be able and willing to discontinue wearing contact lenses for at least 72 hours prior to Visit 2 and for the duration of the visit;
    6. have seasonal allergic conjunctivitis to ragweed or timothy grass documented by a self-reported history of ocular allergic symptoms for the last 2 consecutive years during the ragweed or timothy grass seasons and a positive skin test reaction to ragweed or timothy grass pollen as confirmed by the allergic skin test given at or within 24 months of the subject's Visit 1;
    7. (If female and of ) agree to have urine pregnancy testing performed at visit 2, (must be negative); must not be lactating; and must agree to use at least 1 medically acceptable form of throughout the study duration, for at least 14 days prior to and 1 month after receiving drug. Acceptable forms of birth control are true abstinence (when this is in line with the preferred and usual lifestyle of the subject), spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of male partner at least 3 months prior to receiving investigational drug (Visit 2). Note: Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);
    8. (If male and with female partner of childbearing potential) must use at least 1 medically acceptable form of birth control· Note: Acceptable forms of birth control are true abstinence (when this is in line with the preferred and usual lifestyle of the subject) or vasectomy at least 3 months prior to receiving investigational drug (Visit 2). Without a vasectomy, must use condoms with spermicidal foam/gel/film/cream/suppository throughout the study duration, for at least 14 days prior to and 1 month after investigational drug (Visit 2).
    9. have a calculated visual acuity (VA) of 0.7 logMAR or better in each eye as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Visit 1;
    10. have a positive Allergen BioCube challenge response to pollen exposure at the 90 minute time point of ABC exposure at Visit 2, defined as bilateral score of >2 in ocular itching and ocular redness.

Exclusion criteria

Exclusion Criteria:

  • Subjects may not:

    1. have known or sensitivities to the use of any of the product medication or components;
    2. have a history of mild persistent, moderate or severe asthma within the preceding 5 years according to the National Heart, Blood, and Lung Institute classification (with the exception of exercise induced asthma).

      Note: Subjects with fall induced asthma that is either mild persistent (defined as >1 per week, but \<1 per day), moderate persistent, or severe persistent will be excluded.

    3. have an upper respiratory tract or sinus infection within the previous 2 weeks of Visit 1;
    4. have a history of anaphylaxis or poor tolerability of previously administered allergen;
    5. have a compromised lung function at Visit 1 (defined as a peak expiratory flow rate [PEFR] that is below 80% of the predicted average PEFR, as calculated by gender, age, and measured height from the Mini-Wright instruction's table: Normal Adult Predicted Average Peak Expiratory Flow).
    6. have an abnormal blood pressure (defined as ≤ 90 or ≥ 160 (systolic) measured in mmHg or ≤ 60 or ≥ 100 (diastolic) measured in mmHg) at Visit 1;
    7. have any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters (including but not limited to narrow angle glaucoma, blepharitis, follicular conjunctivitis, iritis, pterygium, or a diagnosis of dry eye);
    8. have had ocular surgical intervention within three months prior to Visit 1, or during the trial or a history of refractive surgery six months prior to Visit 1, or have systemic surgery planned during the clinical trial or within 30 days after;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
229 participants (actual)

Study arms

  • Experimental
    Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

    Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

    Drug: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

  • Experimental
    Ketotifen fumarate ophthalmic solution 0.035%

    Ketotifen fumarate ophthalmic solution 0.035%

    Drug: Ketotifen fumarate ophthalmic solution 0.035%

  • Experimental
    Brimonidine tartrate ophthalmic solution 0.025%

    Brimonidine tartrate ophthalmic solution 0.025%

    Drug: Brimonidine tartrate ophthalmic solution 0.025%

  • Experimental
    Vehicle ophthalmic solution

    Vehicle ophthalmic solution

    Drug: Experimental: Vehicle ophthalmic solution

Interventions

  • DrugBrimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

    Drug page: Brimonidine

    Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution

  • DrugKetotifen fumarate ophthalmic solution 0.035%

    Ketotifen fumarate ophthalmic solution 0.035%

  • Brimonidine tartrate ophthalmic solution 0.025%

  • DrugExperimental: Vehicle ophthalmic solution

    Experimental: Vehicle ophthalmic solution

06

What researchers measure

Primary outcomes

  1. Ocular Itching Symptom Score

    Ocular itching score evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 is the worse outcome.

    Time frame: Assessed up to 480 minutes post-instillation of assigned IP

  2. Ocular Redness Measured by Ocular Itching Scale

    Ocular redness evaluated by the Investigator using slit lamp at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 being the worse outcome.

    Time frame: Assessed up to 480 minutes post-instillation of assigned IP

Secondary outcomes

  1. Tearing Measured by Watery Eyes Scale

    Tearing evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, NOT allowing half unit increments), with 4 being the worse outcome.

    Time frame: up to 480 minutes post-instillation of assigned IP

  2. Lid Swelling Measured by Eyelid Swelling Scale

    Lid swelling evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-3 scale, NOT allowing half unit increments), with 3 being the worst outcome

    Time frame: up to 480 minutes post-instillation of assigned IP

  3. Chemosis Evaluated

    Chemosis evaluated by the Investigator using slit lamp at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 being the worse outcome.

    Time frame: up to 480 minutes post-instillation of assigned IP

07

Results

Posted Jul 1, 2025

Participant flow

Participant flow — Overall Study
MilestoneBrimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic SolutionKetotifen Fumarate Ophthalmic Solution 0.035%Brimonidine Tartrate Ophthalmic Solution 0.025%Vehicle Ophthalmic Solution
Started58575856
Completed57565656
Not completed1120
Withdrew: Screen failure1000
Withdrew: Protocol violation0020
Withdrew: Withdrawal by subject0100

Outcome measures

PrimaryOcular Itching Symptom Score

Ocular itching score evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 is the worse outcome.

Time frame:
Assessed up to 480 minutes post-instillation of assigned IP
Reported as:
Mean · score on a scale
Ocular Itching Symptom Score
score on a scaleBrimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic SolutionKetotifen Fumarate Ophthalmic Solution 0.035%Brimonidine Tartrate Ophthalmic Solution 0.025%Vehicle Ophthalmic Solution
Visit 2, Before Qualification ABC0.175 ± 0.60310.085 ± 0.31360.267 ± 0.75490.098 ± 0.3493
Visit 2, 90 Minutes during Qualification ABC (Baseline)2.728 ± 0.58302.719 ± 0.53102.659 ± 0.45812.647 ± 0.5174
Visit 2, 10 min Post-Instillation1.807 ± 1.05011.808 ± 0.87121.991 ± 1.01632.022 ± 0.8302
Visit 2, 30 min Post-Instillation1.443 ± 0.89141.335 ± 0.82751.513 ± 1.06211.790 ± 0.8979
Visit 2, 60 min Post-Instillation1.110 ± 0.87371.205 ± 0.91711.220 ± 0.94251.438 ± 0.7720
Visit 2, 360 min Post-Instillation0.811 ± 0.85990.723 ± 0.73651.125 ± 0.94851.089 ± 1.0252
Visit 2, 420 min Post-Instillation0.851 ± 0.85680.656 ± 0.73481.078 ± 0.94610.978 ± 0.8624
Visit 2, 480 min Post-Instillation0.961 ± 1.00200.777 ± 0.87861.009 ± 0.91881.063 ± 0.9011
PrimaryOcular Redness Measured by Ocular Itching Scale

Ocular redness evaluated by the Investigator using slit lamp at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 being the worse outcome.

Time frame:
Assessed up to 480 minutes post-instillation of assigned IP
Reported as:
Mean · score on a scale
Ocular Redness Measured by Ocular Itching Scale
score on a scaleBrimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic SolutionKetotifen Fumarate Ophthalmic Solution 0.035%Brimonidine Tartrate Ophthalmic Solution 0.025%Vehicle Ophthalmic Solution
Visit 2, Before Qualification ABC1.218 ± 0.58151.327 ± 0.57711.384 ± 0.58151.268 ± 0.6464
Visit 2, 90 Minutes during Qualification ABC (Baseline)2.469 ± 0.54302.500 ± 0.50452.642 ± 0.58322.478 ± 0.4984
Visit 2, 10 min Post-Instillation1.127 ± 0.82532.116 ± 0.61781.293 ± 0.81942.268 ± 0.6195
Visit 2, 30 min Post-Instillation0.934 ± 0.73881.911 ± 0.64211.103 ± 0.76092.165 ± 0.7011
Visit 2, 60 min Post-Instillation0.904 ± 0.69241.795 ± 0.71841.026 ± 0.75172.098 ± 0.6787
Visit 2, 360 min Post-Instillation1.316 ± 0.82451.723 ± 0.76081.405 ± 0.68961.955 ± 0.6416
Visit 2, 420 min Post-Instillation1.456 ± 0.79361.759 ± 0.78471.582 ± 0.68731.933 ± 0.6440
Visit 2, 480 min Post-Instillation1.553 ± 0.81251.929 ± 0.84711.832 ± 0.77572.063 ± 0.7043
SecondaryTearing Measured by Watery Eyes Scale

Tearing evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, NOT allowing half unit increments), with 4 being the worse outcome.

Time frame:
up to 480 minutes post-instillation of assigned IP
Reported as:
Mean · score on a scale
Tearing Measured by Watery Eyes Scale
score on a scaleBrimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic SolutionKetotifen Fumarate Ophthalmic Solution 0.035%Brimonidine Tartrate Ophthalmic Solution 0.025%Vehicle Ophthalmic Solution
Visit 2, Before Qualification ABC0.12 ± 0.5030.04 ± 0.1970.22 ± 0.7730.13 ± 0.429
Visit 2, 90 Minutes during Qualification ABC (Baseline)1.34 ± 1.1921.23 ± 0.9771.41 ± 1.2191.10 ± 0.997
Visit 2, 10 min Post-Instillation1.21 ± 1.0561.10 ± 0.9881.16 ± 1.0561.14 ± 0.971
Visit 2, 10 min Post-Instillation change from baseline-0.13 ± 0.961-0.13 ± 0.839-0.25 ± 0.7680.04 ± 0.945
Visit 2, 30 min Post-Instillation0.77 ± 0.8350.79 ± 0.8830.94 ± 0.9370.98 ± 0.958
Visit 2, 30 min Post-Instillation change from baseline-0.57 ± 1.006-0.44 ± 0.826-0.47 ± 0.991-0.12 ± 0.853
Visit 2, 60 min Post-Instillation0.66 ± 0.7570.65 ± 0.9090.73 ± 0.8650.76 ± 0.879
Visit 2, 60 min Post-Instillation change from baseline-0.68 ± 0.989-0.58 ± 1.048-0.67 ± 1.024-0.34 ± 0.944
Visit 2, 360 min Post-Instillation0.42 ± 0.6670.41 ± 0.6680.64 ± 0.8830.65 ± 0.744
Visit 2, 360 min Post-Instillation change from baseline-0.92 ± 1.113-0.82 ± 0.811-0.77 ± 1.035-0.45 ± 1.030
Visit 2, 420 min Post-Instillation0.50 ± 0.7260.34 ± 0.5810.68 ± 0.9450.46 ± 0.582
Visit 2, 420 min Post-Instillation change from baseline-0.84 ± 1.123-0.89 ± 0.857-0.72 ± 1.085-0.64 ± 1.065
Visit 2, 480 min Post-Instillation0.54 ± 0.7610.27 ± 0.5390.56 ± 0.7200.46 ± 0.785
Visit 2, 480 min Post-Instillation change from baseline-0.81 ± 1.097-0.96 ± 0.830-0.84 ± 1.056-0.63 ± 1.102
SecondaryLid Swelling Measured by Eyelid Swelling Scale

Lid swelling evaluated by the subject at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-3 scale, NOT allowing half unit increments), with 3 being the worst outcome

Time frame:
up to 480 minutes post-instillation of assigned IP
Reported as:
Mean · score on a scale
Lid Swelling Measured by Eyelid Swelling Scale
score on a scaleBrimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic SolutionKetotifen Fumarate Ophthalmic Solution 0.035%Brimonidine Tartrate Ophthalmic Solution 0.025%Vehicle Ophthalmic Solution
Visit 2, Before Qualification ABC0.09 ± 0.4340.00 ± 0.0000.11 ± 0.4090.04 ± 0.187
Visit 2, 90 Minutes during Qualification ABC (Baseline)1.04 ± 0.9720.70 ± 0.8831.05 ± 0.9210.92 ± 0.873
Visit 2, 10 min Post-Instillation0.85 ± 0.9730.77 ± 0.8741.03 ± 0.9570.98 ± 0.904
Visit 2, 10 min Post-Instillation change from baseline-0.18 ± 0.7480.07 ± 0.606-0.03 ± 0.6520.06 ± 0.714
Visit 2, 30 min Post-Instillation0.75 ± 0.8510.75 ± 0.9050.72 ± 0.7500.90 ± 0.881
Visit 2, 30 min Post-Instillation change from baseline-0.28 ± 0.8510.05 ± 0.644-0.34 ± 0.740-0.02 ± 0.798
Visit 2, 60 min Post-Instillation0.65 ± 0.8020.64 ± 0.8410.59 ± 0.7440.81 ± 0.902
Visit 2, 60 min Post-Instillation change from baseline-0.39 ± 0.835-0.05 ± 0.644-0.47 ± 0.805-0.11 ± 0.785
Visit 2, 360 min Post-Instillation0.48 ± 0.7620.43 ± 0.8170.61 ± 0.8640.67 ± 0.886
Visit 2, 360 min Post-Instillation change from baseline-0.55 ± 0.817-0.27 ± 0.707-0.44 ± 0.869-0.25 ± 0.929
Visit 2, 420 min Post-Instillation0.60 ± 0.8320.44 ± 0.6950.61 ± 0.8380.61 ± 0.824
Visit 2, 420 min Post-Instillation change from baseline-0.44 ± 0.921-0.26 ± 0.681-0.44 ± 0.822-0.31 ± 0.877
Visit 2, 480 min Post-Instillation0.55 ± 0.7770.42 ± 0.7310.55 ± 0.8260.58 ± 0.857
Visit 2, 480 min Post-Instillation change from baseline-0.48 ± 0.802-0.28 ± 0.750-0.50 ± 0.827-0.34 ± 0.895
SecondaryChemosis Evaluated

Chemosis evaluated by the Investigator using slit lamp at 10(±1), 30(±1), 60(±5), 360(±5), 420(±5), and 480(±5) minutes post-instillation of assigned IP at Visit 2 (0-4 scale, allowing half unit increments), with 4 being the worse outcome.

Time frame:
up to 480 minutes post-instillation of assigned IP
Reported as:
Mean · score on a scale
Chemosis Evaluated
score on a scaleBrimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic SolutionKetotifen Fumarate Ophthalmic Solution 0.035%Brimonidine Tartrate Ophthalmic Solution 0.025%Vehicle Ophthalmic Solution
Visit 2, Before Qualification ABC0.000 ± 0.00000.000 ± 0.00000.004 ± 0.03280.022 ± 0.1372
Visit 2, 90 Minutes during Qualification ABC (Baseline)0.298 ± 0.72490.143 ± 0.36260.134 ± 0.38110.129 ± 0.3843
Visit 2, 10 min Post-Instillation0.228 ± 0.58300.121 ± 0.33710.086 ± 0.25020.156 ± 0.4537
Visit 2, 10 min Post-Instillation change from baseline-0.070 ± 0.3196-0.022 ± 0.2490-0.047 ± 0.19570.027 ± 0.3804
Visit 2, 30 min Post-Instillation0.158 ± 0.52740.094 ± 0.31100.039 ± 0.16090.134 ± 0.4290
Visit 2, 30 min Post-Instillation change from baseline-0.140 ± 0.4092-0.049 ± 0.2877-0.095 ± 0.26830.004 ± 0.5319
Visit 2, 60 min Post-Instillation0.154 ± 0.52980.094 ± 0.28830.052 ± 0.19730.112 ± 0.3597
Visit 2, 60 min Post-Instillation change from baseline-0.145 ± 0.4405-0.049 ± 0.2450-0.082 ± 0.2406-0.018 ± 0.4764
Visit 2, 360 min Post-Instillation0.114 ± 0.36620.094 ± 0.29600.069 ± 0.25560.089 ± 0.2756
Visit 2, 360 min Post-Instillation change from baseline-0.184 ± 0.5561-0.049 ± 0.3706-0.065 ± 0.2321-0.040 ± 0.4258
Visit 2, 420 min Post-Instillation0.105 ± 0.35020.067 ± 0.20500.082 ± 0.26240.076 ± 0.2608
Visit 2, 420 min Post-Instillation change from baseline-0.193 ± 0.5408-0.076 ± 0.2564-0.052 ± 0.2555-0.054 ± 0.4439
Visit 2, 480 min Post-Instillation0.088 ± 0.30060.076 ± 0.22320.091 ± 0.26780.058 ± 0.2184
Visit 2, 480 min Post-Instillation change from baseline-0.211 ± 0.5505-0.067 ± 0.2919-0.043 ± 0.2815-0.071 ± 0.4490

Adverse events

Collected over Assessed for approximately 8 hours after treatment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution0/57 (0%)0/57 (0%)1/57 (1.8%)
Ketotifen Fumarate Ophthalmic Solution 0.035%0/56 (0%)0/56 (0%)6/56 (10.7%)
Brimonidine Tartrate Ophthalmic Solution 0.025%0/58 (0%)0/58 (0%)2/58 (3.4%)
Vehicle Ophthalmic Solution0/56 (0%)0/56 (0%)5/56 (8.9%)
Most frequent other events
Most frequent other events
EventBrimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic SolutionKetotifen Fumarate Ophthalmic Solution 0.035%Brimonidine Tartrate Ophthalmic Solution 0.025%Vehicle Ophthalmic Solution
Visual acuity reducedEye disorders1/572/562/582/56
Ocular hyperaemiaEye disorders0/572/560/581/56
Conjunctival oedemaEye disorders0/572/560/580/56
Eyelid exfoliationEye disorders0/570/560/581/56
Erythema of eyelidEye disorders0/570/560/581/56

Baseline characteristics

Age, Continuous
Age, Continuous(years)Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56)Ketotifen Fumarate Ophthalmic Solution 0.035% (n = 56)Brimonidine Tartrate Ophthalmic Solution 0.025% (n = 56)Vehicle Ophthalmic Solution (n = 56)Total
Mean35.5 ± 15.0635.0 ± 12.2837.1 ± 16.0537.1 ± 16.6136.2 ± 15.03
Age, Customized
Age, Customized(Participants)Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56)Ketotifen Fumarate Ophthalmic Solution 0.035% (n = 56)Brimonidine Tartrate Ophthalmic Solution 0.025% (n = 56)Vehicle Ophthalmic Solution (n = 56)Total
Less than 65 years52555550212
Greater or equal to 65 years513615
Sex: Female, Male
Sex: Female, Male(Participants)Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56)Ketotifen Fumarate Ophthalmic Solution 0.035% (n = 56)Brimonidine Tartrate Ophthalmic Solution 0.025% (n = 56)Vehicle Ophthalmic Solution (n = 56)Total
Female34383939150
Male2318191777
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56)Ketotifen Fumarate Ophthalmic Solution 0.035% (n = 56)Brimonidine Tartrate Ophthalmic Solution 0.025% (n = 56)Vehicle Ophthalmic Solution (n = 56)Total
Hispanic or Latino1214141555
Not Hispanic or Latino45424441172
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56)Ketotifen Fumarate Ophthalmic Solution 0.035% (n = 56)Brimonidine Tartrate Ophthalmic Solution 0.025% (n = 56)Vehicle Ophthalmic Solution (n = 56)Total
American Indian or Alaska Native1210121044
Asian13127
Native Hawaiian or Other Pacific Islander00000
Black or African American7791235
White36363431137
More than one race10012
Unknown or Not Reported00202
Region of Enrollment
Region of Enrollment(Participants)Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (n = 56)Ketotifen Fumarate Ophthalmic Solution 0.035% (n = 56)Brimonidine Tartrate Ophthalmic Solution 0.025% (n = 56)Vehicle Ophthalmic Solution (n = 56)Total
United States57565856227
08

Study locations

6 sites
  • 104 Butchertown Clinical Trials
    Louisville, Kentucky 40206, United States
  • 101 Andover Eye Associates
    Andover, Massachusetts 01810, United States
  • 105 - Advancing Vision Research
    Goodlettsville, Tennessee 37072, United States
  • 102 Total Eye Care, PA
    Memphis, Tennessee 38119, United States
  • 108 Emerson Clinical Research Institute Inc.
    Falls Church, Virginia 22046, United States
  • 107 Virginia Eye Institute
    Richmond, Virginia 23230, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Aug 2023, 8 months.

Results were first posted in Jul 2025, 1 year 10 months after primary completion.

Of 21 phase 3 interventional studies under Conjunctivitis, Allergic, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 8 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2022
First posted
Oct 24, 2022
StartActual
Nov 18, 2022
Primary completionActual
Aug 9, 2023
CompletionActual
Aug 9, 2023
Results first posted
Jul 1, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05591755
Responsible party
Sponsor
First posted
Oct 24, 2022
Start date
Nov 18, 2022
Primary completion
Aug 9, 2023
Completion
Aug 9, 2023
Results posted
Jul 1, 2025
Last update
Jul 1, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion